Cogent Biosciences Net Income vs. EBITDA
| COGT Stock | USD 9.51 0.07 0.73% |
Net Loss | First Reported 2017-03-31 | Previous Quarter -59 M | Current Value -70.6 M | Quarterly Volatility 20.3 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 1.1 | 1.15 |
|
|
For Cogent Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cogent Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cogent Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cogent Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cogent Biosciences over time as well as its relative position and ranking within its peers.
Cogent |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cogent Biosciences. If investors know Cogent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cogent Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.48) | Quarterly Revenue Growth (1.00) | Return On Assets (0.44) | Return On Equity (0.78) |
The market value of Cogent Biosciences is measured differently than its book value, which is the value of Cogent that is recorded on the company's balance sheet. Investors also form their own opinion of Cogent Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cogent Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cogent Biosciences' market value can be influenced by many factors that don't directly affect Cogent Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cogent Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cogent Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cogent Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cogent Biosciences EBITDA vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cogent Biosciences's current stock value. Our valuation model uses many indicators to compare Cogent Biosciences value to that of its competitors to determine the firm's financial worth. Cogent Biosciences is rated below average in net income category among its peers. It also is rated below average in ebitda category among its peers . At this time, Cogent Biosciences' Net Loss is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Cogent Biosciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Cogent EBITDA vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Cogent Biosciences |
| = | (192.41 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Cogent Biosciences |
| = | (205.86 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Cogent EBITDA Comparison
Cogent Biosciences is currently under evaluation in ebitda category among its peers.
Cogent Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cogent Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cogent Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Cogent Biosciences' change in net profit over the period of time. It can combine multiple indicators of Cogent Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 246 K | 258.3 K | |
| Operating Income | -208.1 M | -197.7 M | |
| Income Before Tax | -192.4 M | -182.8 M | |
| Net Loss | -192.4 M | -182.8 M | |
| Net Interest Income | 11.3 M | 11.9 M | |
| Interest Income | 11.3 M | 11.9 M | |
| Net Loss | -177.7 M | -168.8 M | |
| Total Other Income Expense Net | 15.7 M | 16.5 M | |
| Income Tax Expense | -6.8 M | -6.5 M | |
| Net Loss | -126.2 M | -132.5 M | |
| Non Operating Income Net Other | 8.7 M | 6.7 M | |
| Change To Netincome | 21.1 M | 21.1 M | |
| Net Loss | (2.42) | (2.54) | |
| Income Quality | 0.80 | 0.40 | |
| Net Income Per E B T | 0.85 | 0.75 |
Cogent Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cogent Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cogent Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cogent Biosciences' important profitability drivers and their relationship over time.
Use Cogent Biosciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cogent Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cogent Biosciences will appreciate offsetting losses from the drop in the long position's value.Cogent Biosciences Pair Trading
Cogent Biosciences Pair Trading Analysis
The ability to find closely correlated positions to Cogent Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cogent Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cogent Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cogent Biosciences to buy it.
The correlation of Cogent Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cogent Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cogent Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cogent Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Cogent Biosciences position
In addition to having Cogent Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Agency Mbs ETFs Thematic Idea Now
Agency Mbs ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Agency Mbs ETFs theme has 11 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Agency Mbs ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.